secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-08-05T11:00:10+00:00
Accession:  0001437749-26-025781
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton licenses late-stage ASN-001 (timolol gel) for infantile hemangiomas; $3M upfront
--------------------------------------------------------------------------------

- Upfront license fee $3M to Auson; milestones up to $33.5M based on sales thresholds; tiered royalties 10-15%.
- Phase II/III trial: 56% (BID) and 42% (TID) elimination/near-elimination at week 24 vs 15% placebo.
- NDA submission planned for 2H 2027; potential approval and launch in 2028.
- Estimated 20,000-30,000 patients annually; complementary to HEMANGEOL, leveraging existing commercial infrastructure.
- Patent protection through 2044; additional patent application pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/0001437749-26-025781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/eton20260803_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer